Current Report Filing (8-k)
04 April 2019 - 6:37AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April 3, 2019 (March 27, 2019)
GUIDED
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-22179
|
58-2029543
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
5835
Peachtree Corners East, Suite B
Norcross,
Georgia 30092
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code:
(770) 242-8723
______________________________________________________
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
[ ]
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
[ ]
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[ ]
|
|
Item
5.02
|
Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory arrangements of Certain Officers
|
On
March 27, 2019, Richard Blumberg, age 63, formally resigned from the Company’s board of directors, effective as of that
date. Mr. Blumberg was appointed to the board in 2016. His decision to resign was for personal reasons and was not a result of
any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GUIDED
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
Date: April
3, 2019
|
By:
/s/ Gene
S. Cartwright, Ph.D.
|
|
|
Name: Gene
S. Cartwright, Ph.D.
|
|
|
Title: President,
Chief Executive Officer and Director
|
|
|
|
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Feb 2025 to Mar 2025
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Mar 2024 to Mar 2025
